98%
921
2 minutes
20
Background: Little is known about antidysrhythmic administration disparities for out-of-hospital cardiac arrest (OHCA).
Objectives: We evaluated the association between combined lower-income and minoritized communities with antidysrhythmic administration for OHCA.
Methods: We studied the 2018-2021 National Emergency Medical Services Information System encounters, linked to census data. We included adult OHCAs with a shockable rhythm. We used encounter ZIP Code data to calculate household income quartiles (Q1-highest to Q4-lowest). We created combined income and race/ethnicity strata, yielding 6 cohorts and 2 ordered groups (1-4a [Black] and 1-4b [Hispanic] with 1 and 2 shared between them): 1) Q1 income/>70% White, 2) Q2 income/50%-70% White, 3a) Q3 Income/50%-70% Black, 4a) Q4 Income/>70% Black, 3b) Q3 Income/50%-70% Hispanic, and 4b) Q4 income/>70% Hispanic. We evaluated the association of combined income and race/ethnicity groups to administration of an antidysrhythmic, with cohort 1 as the reference.
Results: We included 61,437 OHCAs. Compared to Q1 income/>70% White (33.5%), Q2 income/50-70% White had higher odds of antidysrhythmic administration (36.0%, aOR 1.15 [1.1-1.2]). However, all other groups had lower odds of antidysrhythmic administration (Q3 income/50-70% Black - 28.1%, aOR 0.8 [0.7-0.9]; Q4 income/>70% Black - 29.6%, aOR 0.9 [0.8-0.95]; Q3 income/50-70% Hispanic - 31.1%, aOR 0.9 [0.8-0.99]; Q4 income/>70% Hispanic - 23.0%, aOR 0.6 [0.6-0.7]). Using ordinal regression, decreasing income and increasing Black race (aOR 0.95[0.9-0.97]) as well as decreasing income and increasing Hispanic ethnicity (aOR 0.9 [0.9-0.95]) in a community were associated with decreased odds of antidysrhythmic administration CONCLUSION: Decreasing household income and increasing minoritized race/ethnicity were associated with decreased odds of antidysrhythmic administration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jemermed.2025.05.016 | DOI Listing |
J Emerg Med
August 2025
Department of Family & Community Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Background: Little is known about antidysrhythmic administration disparities for out-of-hospital cardiac arrest (OHCA).
Objectives: We evaluated the association between combined lower-income and minoritized communities with antidysrhythmic administration for OHCA.
Methods: We studied the 2018-2021 National Emergency Medical Services Information System encounters, linked to census data.
Clin Toxicol (Phila)
September 2024
American College of Medical Toxicology, Phoenix, AZ, USA.
Introduction: Tricyclic antidepressants often cause drug-induced QRS complex prolongation in overdose but are now less commonly prescribed. We sought to determine, among a contemporary cohort of patients, the pharmaceuticals independently associated with QRS complex prolongation in acute overdose.
Methods: We performed secondary analysis of data from the Toxicology Investigators Consortium (ToxIC) Core Registry.
Chem Res Toxicol
May 2022
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P. R. China.
Propafenone (PPF) is a class I antidysrhythmic drug, which is commonly used for the treatment of atrial fibrillation and other supraventricular arrhythmias. It is also a β-adrenoceptor antagonist that can cause bradycardia and bronchospasm. Hepatotoxicity is one of the adverse reactions reported, with clinical manifestations including acute cholestasis and hepatocyte necrosis.
View Article and Find Full Text PDFAnn Emerg Med
July 2020
Department of Emergency Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY; Department of Emergency Medicine, Kings County Hospital Center, Brooklyn, NY.
Study Objective: We conduct a systematic review and Bayesian network meta-analysis to indirectly compare and rank antidysrhythmic drugs for pharmacologic cardioversion of recent-onset atrial fibrillation and atrial flutter in the emergency department (ED).
Methods: We searched MEDLINE, EMBASE, and Web of Science from inception to March 2019, limited to human subjects and English language. We also searched for unpublished data.
J Emerg Med
October 2018
Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota.
Background: Treatment for epistaxis includes application of intranasal vasoconstrictors. These medications have a precaution against use in patients with hypertension. Given that many patients who present with epistaxis are hypertensive, these warnings are commonly overridden by clinical necessity.
View Article and Find Full Text PDF